Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 23

Trial readouts

SLIM LIVER: Semaglutide and HIV

SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

SURPASS-CVOT Beyond MACE

A 2026 commentary argues that SURPASS-CVOT may require endpoints beyond MACE, but its biological framework remains a hypothesis, not new trial evidence.

17 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide With Biologics in PsA

A matched 2026 study linked concurrent tirzepatide and biologic initiation with better six-month outcomes in obese psoriatic arthritis.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Emerging knee OA therapies: review map

A 2026 review maps semaglutide, local GLP-1 candidates, gene therapy and other emerging knee osteoarthritis treatments.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 drugs and dental evidence gaps

A 2026 appraisal found promising preclinical dental findings for GLP-1 drugs, but no prospective patient study with a dental endpoint.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Low-dose tirzepatide in older adults

A 28-week Japanese cohort found high persistence and modest metabolic change with low-dose tirzepatide in selected older adults.

16 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Obesity and knee OA: what review found

A narrative review places semaglutide evidence inside broader weight-management care for people with obesity and knee osteoarthritis.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Oral semaglutide and needle phobia

A 2026 review examines oral semaglutide for people with needle phobia, but it reports no new head-to-head trial or adherence outcome.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Peptides in three dental nerve cases

Three dental nerve-injury cases improved during a multi-agent peptide intervention, but the uncontrolled report cannot establish efficacy.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Retatrutide in a diabetic rat kidney study

A 2026 rat study found a kidney HIF-1α change with retatrutide, but no statistically confirmed protection against tissue injury.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Rural GLP-1 chart review: 40 adults

A 40-person rural chart review linked tirzepatide or semaglutide use with improved A1c and several cardiometabolic measures.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 drugs in schizophrenia: 7 trials

Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.

16 Oct 2026 · PeptideMethods Editorial Team · 4 min read